Deep vein thrombosis

  • Hazzaa Al-Zahrani
  • Shannon M. Bates
  • Jeffrey I. Weitz
Article

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Brandjes DP, Heijboer H, Buller HR, et al.: Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992, 327:1485–1489.PubMedCrossRefGoogle Scholar
  2. 2.
    Koopman MMW, Prandoni P, Piovella F, et al.: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996, 334:682–687. In this study, 400 patients with acute proximal deep vein thrombosis were randomly assigned to receive adjusted-dose intravenous unfractionated heparin therapy administered in the hospital or fixed-dose subcutaneous low-molecularweight heparin (LMWH) administered at home. Recurrent thromboembolism and major bleeding developed in 8.6% and 2%, respectively, of patients administered unfractionated heparin and in 6.9% and 2% of those randomized to receive LMWH. LMWH treatment was associated with a mean reduction in hospital stay of 67%, and 36% of patients were never admitted to the hospital.PubMedCrossRefGoogle Scholar
  3. 3.
    Levine M, Gent M, Hirsh J, et al.: A comparison of lowmolecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996, 334:677–681. In this study, 500 patients with acute proximal deep vein thrombosis were randomly assigned to receive either intravenous unfractionated heparin in the hospital or low-molecular-weight heparin (LMWH, twice-daily subcutaneous enoxaparin in a dose of 1 mg/kg) administered primarily at home. Recurrent venous thromboembolism developed in 5.3% of patients administered LMWH compared with 6.7% of those administered unfractionated heparin (P = 0.57). Major bleeding occurred in five patients given LMWH and in three patients randomized to receive unfractionated heparin. Patients administered LMWH spent a mean of 1.1 days in the hospital, compared with 6.5 days for those administered unfractionated heparin.PubMedCrossRefGoogle Scholar
  4. 4.
    Lagerstedt CI, Olsson CG, Fagher BO, et al.: Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985, 2:515–518.PubMedCrossRefGoogle Scholar
  5. 5.
    Hull R, Delmore T, Genton E, et al.: Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979, 301:855–858.PubMedCrossRefGoogle Scholar
  6. 6.
    Hull R, Delmore T, Carter C, et al.: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982, 306:189–194.PubMedCrossRefGoogle Scholar
  7. 7.
    Pini M, Aiello S, Manotti C, et al.: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemostasis 1994, 72:191–197.Google Scholar
  8. 8.
    Monreal M, Lafoz E, Olive A, et al.: Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemostasis 1994, 71:7–11.Google Scholar
  9. 9.
    Douketis JD, Kearon C, Bates S, et al.: Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998, 279:458–462.PubMedCrossRefGoogle Scholar
  10. 10.
    Ginsberg JS: Management of venous thromboembolism. N Engl J Med 1996, 335:1816–1828. This is an excellent review of the management of patients with venous thromboembolism.PubMedCrossRefGoogle Scholar
  11. 11.
    Hull RD, Raskob GE, Brant RF, et al.: Relation between the time to achieve the lower limit of the aPTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997, 157:2562–2568.PubMedCrossRefGoogle Scholar
  12. 12.
    Hirsh J, Fuster V: Guide to anticoagulant therapy, I: heparin. Circulation 1994, 89:1449–1468.PubMedGoogle Scholar
  13. 13.
    Basu D, Gallus A, Hirsh J, et al.: A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972, 287:324–327.PubMedCrossRefGoogle Scholar
  14. 14.
    D’Angelo A, Seveso MP, D’Angelo SV, et al.: Effect of clot-detection methods and reagents on activated partial thromboplastin time (aPTT): implications in heparin monitoring by aPTT. Am J Clin Pathol 1990, 94:297–306.PubMedGoogle Scholar
  15. 15.
    Raschke RA, Reilly BM, Guidry JR, et al.: The weightbased heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 1993, 119:874–881.PubMedGoogle Scholar
  16. 16.
    Hommes DW, Bura A, Mazzolai L, et al.: Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: a meta-analysis. Ann Intern Med 1992, 116:279–284.PubMedGoogle Scholar
  17. 17.
    Levine M, Raskob GE, Landefeld CS, Hirsh J: Hemorrhagic complications of anticoagulant treatment. Chest 1995, 108(suppl):291S-302S.PubMedGoogle Scholar
  18. 18.
    Warkentin TE: Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998, 35:17–25.PubMedGoogle Scholar
  19. 19.
    Levine MN, Hirsh J, Gent M, et al.: A randomized trial comparing the activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994, 154:49–56.PubMedCrossRefGoogle Scholar
  20. 20.
    Young E, Prins M, Levine MN, et al.: Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemostasis 1992, 67:639–643.Google Scholar
  21. 21.
    Weitz JI: Low-molecular-weight heparins. N Engl J Med 1997, 337:688–698. This article is a comprehensive review of low-molecularweight heparins.PubMedCrossRefGoogle Scholar
  22. 22.
    Laposata M, Green D, Van Cott EM, et al.: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecularweight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998, 122:799–807.PubMedGoogle Scholar
  23. 23.
    Warkentin TE, Levine MN, Hirsh J: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330–1335.PubMedCrossRefGoogle Scholar
  24. 24.
    Holst J, Lindblad B, Bergqvist D, et al.: Protamine neutralization of intravenous and subcutaneous lowmolecular-weight heparin (tinzaparin, Logiparin): an experimental investigation in healthy volunteers. Blood Coagul Fibrinolysis 1994, 5:795–803.PubMedCrossRefGoogle Scholar
  25. 25.
    Turpie AG: Pharmacology of the low-molecular-weight heparins. Am Heart J 1998, 135:S329-S333.PubMedCrossRefGoogle Scholar
  26. 26.
    Rodger M, Bredeson C, Wells PS, et al.: Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. Can Med Assoc J 1998, 159:931–938.Google Scholar
  27. 27.
    Meuleman DG: Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis 1992, 22:58–65.PubMedGoogle Scholar
  28. 28.
    Danhof M, de Boer A, Magnani HN, et al.: Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992, 22:73–84.PubMedGoogle Scholar
  29. 29.
    Moia M, Sciele F, Walter M, et al. on behalf of the International Multicentre Hirudin Study Group: Treatment of acute deep vein thrombosis (DVT) by subcutaneous r-Hirudin (HBW 023): a multicentre study. Thromb Haemostasis 1995, 73:1456.Google Scholar
  30. 30.
    Parent F, Bridley F, Dreyfus M, et al.: Treatment of severe venous thromboembolism with intravenous Hirudin (HBW 023): an open pilot study. Thromb Haemostasis 1993, 70:386–388.Google Scholar
  31. 31.
    Schiele F, Vuillemenot A, Kramarz P, et al.: A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemostasis 1994, 71:558–562.Google Scholar
  32. 32.
    Schiele F, Vuillemenot A, Kramarz P, et al.: Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Haematol 1995, 50:24–29.CrossRefGoogle Scholar
  33. 33.
    Nand S: Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am J Haematol 1993, 43:310–311.CrossRefGoogle Scholar
  34. 34.
    Warkentin TE, Chong BH, Greinacher A: Heparininduced thrombocytopenia: towards consensus. Thromb Haemostasis 1998, 79:1–7.Google Scholar
  35. 35.
    Comerrota AJ, Aldridge SC, Cohen G, et al.: A strategy of aggressive regional therapy for acute iliofemoral venous thrombosis with contemporary venous thrombectomy or catheter directed thrombolysis. J Vasc Surg 1994, 20:244–254.Google Scholar
  36. 36.
    Verhaeghe R, Stockx L, Lacroix H, et al.: Catheterdirected lysis of iliofemoral vein thrombosis with use of rt-PA. Eur Radiol 1997, 7:996–1001.PubMedCrossRefGoogle Scholar
  37. 37.
    Heymans S, Verhaege R, Stockx L, Collen D: Feasibility of catheter-directed thrombolysis with recombinant staphylokinase in deep venous thrombosis. Thromb Haemostasis 1998, 79:517–519.Google Scholar
  38. 38.
    Mewissen MW, Seabrook GR, Meissner HN, Haughton SH: Catheter directed thrombolysis for symptomatic lower extremity deep vein thrombosis [abstract]. Blood 1998, 92:501a.Google Scholar
  39. 39.
    Levine MN: Thrombolytic therapy for venous thromboembolism: complications and contraindications. Clin Chest Med 1995, 16:321–328.PubMedGoogle Scholar
  40. 40.
    Decousus H, Leizorovicz A, Parent F, et al.: A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis: Prevention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998, 338:409–415. In this study, 400 patients with proximal deep vein thrombosis who were at risk for pulmonary embolism were randomized to receive a vena caval filter or no filter and to receive low-molecular-weight heparin (enoxaparin) or unfractionated heparin. The initial beneficial effect of vena caval filters in preventing pulmonary embolism was counterbalanced by an excess of recurrent deep vein thrombosis. There was no difference in mortality rates.PubMedCrossRefGoogle Scholar
  41. 41.
    Hirsh J, Fuster V: Guide to anticoagulant therapy, II: oral anticoagulants. Circulation 1994, 89:1469–1480.PubMedGoogle Scholar
  42. 42.
    Harrison L, Johnston M, Massicotte MP, et al.: Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997, 126:133–136.PubMedGoogle Scholar
  43. 43.
    Saour JN, Sieck JO, Mamo LA, et al.: Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990, 322:428–432.PubMedCrossRefGoogle Scholar
  44. 44.
    Broekmans AW, Bertina RM, Loeliger EA, et al.: Protein C and the development of skin necrosis during anticoagulant therapy [letter]. Thromb Haemostasis 1983, 49:251.Google Scholar
  45. 45.
    Kearon C: Duration of anticoagulation in venous thromboembolism. In Critical Decisions in Thrombosis and Hemostasis. Edited by Ginsberg J, Kearon C, Hirsh J. Boston: Blackwell Science; 1998:87–92.Google Scholar
  46. 46.
    Ginsberg JS, Hirsh J: Use of antithrombotic agents during pregnancy. Chest 1998, 114:524S-530S.PubMedGoogle Scholar
  47. 47.
    Ginsberg JS, Hirsh J, Turner DC, et al.: Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemostasis 1989, 61:197–203.Google Scholar
  48. 48.
    Schneider DM, von Tempelhoff GF, Heilmann L: Retrospective evaluation of the safety and efficacy of lowmolecular-weight heparin as thromboprophylaxis during pregnancy. Am J Obstet Gynecol 1997, 177:1567–1568.PubMedCrossRefGoogle Scholar
  49. 49.
    Bates SM, Ginsberg JS: Anticoagulants in pregnancy: fetal effects. Baillieres Clin Obstet Gynaecol 1997, 11:479–488.PubMedCrossRefGoogle Scholar
  50. 50.
    Bates SM, Ginsberg JS: The special problems of thromboembolism in pregnancy. IM Intern Med 1997, 18:121–133.Google Scholar

Copyright information

© Current Science Inc. 1999

Authors and Affiliations

  • Hazzaa Al-Zahrani
    • 1
  • Shannon M. Bates
    • 1
  • Jeffrey I. Weitz
    • 1
  1. 1.Hamilton Civic Hospitals Research CentreHamiltonCanada

Personalised recommendations